Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases

Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma and...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Leelawat, Kawin, Narong, Siriluck, Wannaprasert, Jerasak, Leelawat, Surang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE-Hindawi Access to Research 2011
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3170848/
https://ncbi.nlm.nih.gov/pubmed/21994874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4061/2011/873548
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller